SarcopeniaNCT03417609
Interest of a Tongue Strength Measurement in the Screening for Sarcopenia in Hospitalized Elderly Patients
An observational study of Sarcopenia, run by Murielle Surquin at 1 site in Belgium.
Trial summary
Sarcopenia is a syndrome characterized by a progressive and generalized loss of skeletal muscle mass, strength and function that increases the risk of physical dependence, impaired quality of life and mortality. This is a major public health problem. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Sarcopenia
- What is being tested?
- Tongue strength measurement, Blood sampling and Mini Mental State Examination (MMSE)
- Type of treatment
- Pill or oral medicine, Medical device, Surgery or procedure
- How many people
- 110 participants
- Where
- 1 siteBelgium
- Study dates
- 7 Feb 2018to 1 Jan 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Patients hospitalized in an acute geriatric unit within the CHU Brugmann.
Who may be able to join
- Patients hospitalized in an acute geriatric unit within the CHU Brugmann.
Who cannot join
- None
Trial locations and contacts
1 site in 1 country.
About this study
Sarcopenia is a syndrome characterized by a progressive and generalized loss of skeletal muscle mass, strength and function that increases the risk of physical dependence, impaired quality of life and mortality. This is a major public health problem. Indeed, its prevalence has been estimated at 63.8% for elderly patients hospitalized in acute geriatric unit.
Several methods of sarcopenia screening exist at present. The European Working Group on Sarcopenia in Older People (EWGSOP) proposes to carry out three examinations for the diagnosis of sarcopenia: the Dual-Energy X-ray Absorptiometry (DEXA) test and two motor tests (walking speed and hand test). These measurements have already been evaluated and validated. They are reliable, inexpensive and easily achievable in clinical routine.
Read more
Recent studies have shown that decreased muscle mass and / or strength could be associated with dysphagia. Indeed, many muscles of the head and neck are simultaneously solicited for swallowing coordination. This suggests that a reduction in the mass or strength of these muscles could impact the swallowing function. The investigator's hypothesize that loss of lingual muscle strength may be associated with sarcopenia. The study will measure the tongue strength using the Iowa Oral Performance Instrument (IOPI) in a geriatric population with or without sarcopenia.
- Determine the incidence of lingual hypotonia in hospitalized elderly sarcopenia patients.
- To compare the sensitivity, the specificity of the measurement of the force of the tongue with the usual measures proposed by the EWGSOP in the context of screening for sarcopenia.
- Conditions
- Sarcopenia
- Being tested
- Tongue strength measurement, Blood sampling, Mini Mental State Examination (MMSE), Minimal nutritional assessment (MNA-SF), Dual-energy x-ray absorptiometry (DEXA)
- Keywords
- Sarcopenia, Tongue strength
- Medical subject headings
- Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tongue strength measurementDevice
The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it.
Blood samplingProcedure or surgery
Blood sampling
Mini Mental State Examination (MMSE)Diagnostic test
Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items.
Minimal nutritional assessment (MNA-SF)Diagnostic test
The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient.
Dual-energy x-ray absorptiometry (DEXA)Diagnostic test
Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia.
Dynamometer (Hand grip )Device
By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.
Walking speedDiagnostic test
Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party.
| Study group | Role | What they receive |
|---|---|---|
| Sarcopenia | Elderly patients with sarcopenia Receives: Device: Tongue strength measurement; Procedure: Blood sampling; Diagnostic Test: Mini Mental State Examination (MMSE); Diagnostic Test: Minimal nutritional assessment (MNA-SF); Diagnostic Test: Dual-energy x-ray absorptiometry (DEXA); Device: Dynamometer (Hand grip ); Diagnostic Test: Walking speed | |
| Control | Elderly patients without sarcopenia Receives: Device: Tongue strength measurement; Procedure: Blood sampling; Diagnostic Test: Mini Mental State Examination (MMSE); Diagnostic Test: Minimal nutritional assessment (MNA-SF); Diagnostic Test: Dual-energy x-ray absorptiometry (DEXA); Device: Dynamometer (Hand grip ); Diagnostic Test: Walking speed |
What is being measured
The primary outcome is the main question the study is designed to answer.
Tongue strength
The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it. Thus, a pressure measurement expressed in kPa makes it possible to objectify the tongue strength.
Measured: 6 months
Secondary outcomes (7)
Pre-Albumin concentration
Albumin and pre-albumin are biological markers for undernutrition. Pre-albumin is an earlier marker than albumin because of its shorter half-life, 48 hours versus 21 days. The normal pre-albumin values are between 200 and 400 mg /L, undernutrition is serious if it is less than 150mg/dL.
Measured: 6 months
Albumin concentration
Albumin and pre-albumin are biological markers for undernutrition. Pre-albumin is an earlier marker than albumin because of its shorter half-life, 48 hours versus 21 days.The normal values of albumin are between 40 and 45g/L, between 30 and 35g/L there is moderate undernutrition and under 30g/L it is severe undernutrition.
Measured: 6 months
Mini Mental State Examination (MMSE) score
Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items: Orientation ability - Learning and transcription skills - Attention and calculation skills - Memory retention capacity - Language and naming capability - Constructive Praxy.
A MMSE score over 27 indicates normal cognitive functions (maximum: 29). A MMSE score between 24 and 27 indicates mild cognitive impairment. A MMSE score under 24 indicates dementia.
Measured: 6 months
Minimal nutritional assessment (MNA-SF) score
The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient. It takes into account the patient's loss of appetite, weight loss, motor skills, recent health status, neuropsychological disorders
The maximum score of the MNA-SF is 14:
- Greater than or equal to 11: normal nutritional status.
- Between 8 and 11: risk of malnutrition.
- Less than 8: proven malnutrition.
Measured: 6 months
Skeletal Mass Muscle Index
Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia. It gives minimal irradiation and gives an adequate estimate of the appendicular muscle mass (ALM). By dividing the ALM by the size in centimeters, we obtain the Skeletal Mass Muscle Index (SMI). SMI values below 2 standard deviations from the mean point towards sarcopenia.
Measured: 6 months
Hand grip strength
By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.
Measured: 6 months
Walking speed
Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party. It has been shown that there is a non-linear relationship between walking speed and muscle strength.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2018
- Study start7 Feb 2018
- Primary completion1 Jan 2019
- Study completion1 Jan 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 110 participants (actual)
Sponsor and investigators
- Lead sponsor
- Murielle Surquin
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Murielle Surquin, Brugmann University Hospital
- Investigators
- Alexandrine de Buck van Overstraeten, MD, Principal investigator, CHU Brugmann
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03417609
- Sponsor's protocol ID
- CHUB-sarcopenia-tongue
- Status last verified
- Apr 2019
- First submitted
- 25 Jan 2018
- Last updated
- 4 Apr 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Interest of a Tongue Strength Measurement in the Screening for Sarcopenia in Hospitalized Elderly Patients
- ClinicalTrials.gov ID
- NCT03417609
- Acronym / sponsor ID
- CHUB-sarcopenia-tongue
- Conditions
- Sarcopenia
- Keywords
- Sarcopenia, Tongue strength
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 110 participants (actual)
- Lead sponsor
- Murielle SurquinUniversity, hospital or other
- Study start
- 7 Feb 2018 (actual)
- Primary completion
- 1 Jan 2019 (actual)
- Study completion
- 1 Jan 2019 (actual)
- First posted
- 31 Jan 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sarcopenia is a syndrome characterized by a progressive and generalized loss of skeletal muscle mass, strength and function that increases the risk of physical dependence, impaired quality of life and mortality. This is a major public health problem. Indeed, its prevalence has been estimated at 63.8% for elderly patients hospitalized in acute geriatric unit.
Several methods of sarcopenia screening exist at present. The European Working Group on Sarcopenia in Older People (EWGSOP) proposes to carry out three examinations for the diagnosis of sarcopenia: the Dual-Energy X-ray Absorptiometry (DEXA) test and two motor tests (walking speed and hand test). These measurements have already been evaluated and validated. They are reliable, inexpensive and easily achievable in clinical routine.
Recent studies have shown that decreased muscle mass and / or strength could be associated with dysphagia. Indeed, many muscles of the head and neck are simultaneously solicited for swallowing coordination. This suggests that a reduction in the mass or strength of these muscles could impact the swallowing function. The investigator's hypothesize that loss of lingual muscle strength may be associated with sarcopenia. The study will measure the tongue strength using the Iowa Oral Performance Instrument (IOPI) in a geriatric population with or without sarcopenia.
- Determine the incidence of lingual hypotonia in hospitalized elderly sarcopenia patients.
- To compare the sensitivity, the specificity of the measurement of the force of the tongue with the usual measures proposed by the EWGSOP in the context of screening for sarcopenia.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sarcopenia | – | Device: Tongue strength measurement, Procedure: Blood sampling, Diagnostic Test: Mini Mental State Examination (MMSE), Diagnostic Test: Minimal nutritional assessment (MNA-SF), Diagnostic Test: Dual-energy x-ray absorptiometry (DEXA), Device: Dynamometer (Hand grip ), Diagnostic Test: Walking speedElderly patients with sarcopenia |
| Control | – | Device: Tongue strength measurement, Procedure: Blood sampling, Diagnostic Test: Mini Mental State Examination (MMSE), Diagnostic Test: Minimal nutritional assessment (MNA-SF), Diagnostic Test: Dual-energy x-ray absorptiometry (DEXA), Device: Dynamometer (Hand grip ), Diagnostic Test: Walking speedElderly patients without sarcopenia |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Patients hospitalized in an acute geriatric unit within the CHU Brugmann.
Key inclusion criteria (1 listed)
- Patients hospitalized in an acute geriatric unit within the CHU Brugmann.
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tongue strength measurementThe Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it. | Device | Control, Sarcopenia |
| Blood samplingBlood sampling | Procedure or surgery | Control, Sarcopenia |
| Mini Mental State Examination (MMSE)Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items. | Diagnostic test | Control, Sarcopenia |
| Minimal nutritional assessment (MNA-SF)The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient. | Diagnostic test | Control, Sarcopenia |
| Dual-energy x-ray absorptiometry (DEXA)Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia. | Diagnostic test | Control, Sarcopenia |
| Dynamometer (Hand grip )By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated. | Device | Control, Sarcopenia |
| Walking speedWalking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party. | Diagnostic test | Control, Sarcopenia |
Primary outcome
Tongue strength
Time frame: 6 months
The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it. Thus, a pressure measurement expressed in kPa makes it possible to objectify the tongue strength.
7 secondary outcomes
Pre-Albumin concentration
Time frame: 6 months
Albumin concentration
Time frame: 6 months
Mini Mental State Examination (MMSE) score
Time frame: 6 months
Minimal nutritional assessment (MNA-SF) score
Time frame: 6 months
Skeletal Mass Muscle Index
Time frame: 6 months
Hand grip strength
Time frame: 6 months
Walking speed
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2019.
- Individual participant dataSharing planned: No
Related trials for Sarcopenia
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexandrine de Buck van Overstraeten, MD principal investigator
CHU Brugmann
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcopenia, run by Murielle Surquin at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Tongue strength (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2019.